10/11/2017

Sodium Nitroprusside Injection

Reason for the Shortage

- Akorn has sodium nitroprusside 25 mg/mL 2 mL vials available.
- Exela launched Nipride RTU 0.5 mg/mL 100 mL vials in March 2017.
- Nexus has sodium nitroprusside 25 mg/mL 2 mL vials available.
- Sagent has sodium nitroprusside 25 mg/mL 2 mL vials available.
- Valeant has Nitropress available.

Available Products

- Nipride RTU injection, Exela Pharma Sciences, 0.5 mg/mL, 100 mL ready-to-use vial, 1 count, NDC 51754-1006-01
- Nitropress injection, Valeant, 25 mg/mL, 2 mL vial, 1 count, NDC 00187-4302-02
- Sodium Nitroprusside injection, Akorn, 25 mg/mL, 2 mL vial, 1 count, NDC 17478-0014-02
- Sodium Nitroprusside injection, Nexus Pharmaceuticals, 25 mg/mL, 2 mL vial, 1 count, NDC 14789-0012-02
- Sodium Nitroprusside injection, Sagent, 25 mg/mL, 2 mL vial, 1 count, NDC 25021-0310-02

Estimated Resupply Dates

- All presentations are available.

Updated

Updated October 11, 2017 by Leslie Jensen, PharmD, Drug Information Specialist. Created December 30, 2015 by Michelle Wheeler, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.